proviron steroid

08/24/2016

Recombinant human interferon gamma, consists of , and deprived of the first three. about. , replaced on Met. The molecular weight of . Microbially synthesis in recombinant Escherichia coli strain and purified by column chromatography. The specific antiviral activity proviron steroid on cells (human fibroblasts) infected with vesicular stomatitis virus is units per mg protein.
The receptors of interferon gamma are macrophages, neutrophils, natural killer cells, cytotoxic T-lymphocytes. Interferon gamma activates the effector functions of these cells, in particular their mikrobotsidnost, cytotoxicity, cytokine production, and nitroxide superoxide radicals, thereby causing the death of intracellular parasites. Interferon gamma inhibits Activates production of acute phase proteins, inflammation, enhances gene expression of  components proviron steroid of the complement system.
Unlike other interferons increase expression of antigens by MHC as the I-st and the II-th classes in different cells, and induces the expression of these molecules, even those cells that do not express them constitutively. This increases the efficiency of antigen presentation and the ability of their recognition by T lymphocytes. Interferon proviron steroid gamma blocking viral DNA replication and RNA synthesis of viral proteins and assembly of mature virus particles. Interferon gamma has a cytotoxic effect on the virus-infected cells.
Interferon Gamma blocks the synthesis of ß-TGF, responsible for the development of pulmonary fibrosis and liver.

Indications
Treatment of chronic hepatitis C, chronic hepatitis B, HIV / AIDS infection and pulmonary tuberculosis in combination therapy.
Prevention of infectious complications in patients with chronic granulomatous disease.
The treatment of cancer in combination therapy as an immunomodulator, including in combination with chemotherapy.
Treatment of genital herpes infection and shingles (herpes zoster) in monotherapy.
Treatment of urogenital chlamydiosis proviron steroid in complex therapy.

Contraindications
Individual intolerance to interferon gamma, or any other component of the drug. Pregnancy. Autoimmune disease. Diabetes.

Dosing and Administration
The introduction of the drug intramuscularly or subcutaneously.
The contents of the vial is dissolved in 2 ml of water for injection.
The dose is determined individually.
For the treatment of patients with chronic viral hepatitis B, chronic hepatitis C, and HIV / AIDS infection and pulmonary tuberculosis average daily intake for adults is 500 000 ME. Introduced 1 time a day, every day or every other day. The course of treatment is from 1 to 3 months, if necessary, after 1-2 months, repeat the treatment.
For the prevention of infectious complications in patients with chronic granulomatous disease usually mean daily dose for adults is the ME 500000. Introduced 1 time a day, every proviron steroid day or every other day. In the course of 5-15 injections, if necessary, extend or repeat the course in 10-14 days.
For the treatment of cancer, the mean daily dose for adults is the ME 500000. We introduce the 1 times a day every other day.
For the treatment of genital herpes virus infection, shingles (herpes zoster) and urogenital chlamydiosis average daily dose for adults is the ME 500000. Introduced 1 time per day subcutaneously every other day. The course of treatment is 5 injections.

Side effects
Local pain at the site of subcutaneous injection in the form of mild pain bursting nature (similar to overtrain the muscle) and flushing.
The use of high doses of more than 1,000,000 ME may be accompanied by the development of a flu-like syndrome: headache, weakness, fever, pain in the joints. Mild symptoms do not require pharmacological correction. When expressed phenomena – relief using paracetamol.

Release form
Valium for drug of a solution for intramuscular or subcutaneous injection in vials of 100,000 ME, 500000 ME, ME 1000000 or 2000000 ME active ingredient per 1 vial. 1, 5, 10 or 20 vials proviron steroid of drug with instructions for use placed in a pile of cardboard, or at 1, 5, 10 or 20 vials of drug in blisters or cassette contour packaged with instructions for use placed in a pile of cardboard.

Storage conditions
In a dry place, protected from light and the reach of children, at a temperature of 2-10 ° C. Do not freeze

Shelf life
2 years. Do not use after the expiration date.

Terms of pharmacies holiday
Dispensed by prescription. Running low dose t3 clen cycle trying to lose bodyfat isn’t a real hot idea imo.

buy proviron

08/24/2016

It has antiviral action and is effective against influenza viruses types A and B, adenovirus infection. In the experiment, in vitro and in vivo to effectively inhibit cytopathic effect and reproduction of influenza viruses types A and B, adenovirus. The antiviral buy proviron mechanism of action – inhibition of viral replication in the nuclear stage, delayed migration of newly synthesized viral from the cytoplasm to the nucleus. It has a modulating effect on the functional activity of the interferon system: causes an increase in blood interferon to the physiological norm, stimulates and normalizes reduced as interferon-producing ability of white blood cells, it stimulates gamma-interferon-producing ability of white blood cells. It causes generation of cytotoxic lymphocytes, and increases the content of  cells having a high killer activity against transformed cells and viruses pronounced antiviral activity. The anti-inflammatory effect is due to inhibition of the production of key proinflammatory cytokines, decrease buy proviron miepoperoksidazy activity. The therapeutic efficacy of the flu appears in the shortened period pihoradki, reduction of intoxication (headache, weakness, dizziness), catarrhal symptoms, reducing the number of complications and duration of the disease in general.

The conducted toxicological studies indicate low toxicity and high safety profile of the drug . It was found that the drug is not mutagenic and carcinogenic, does not affect reproductive function does not have immunotoxic and allergenic properties, has no local irritating action.

Pharmacokinetics
The determination of the recommended doses of the drug in the blood plasma of available techniques is not possible. In an experiment using a radioactive label, it was established that the drug rapidly enters the bloodstream from the gastrointestinal tract. Evenly raspredepyaetsya to internal organs. The maximum blood concentration, blood and most organs plasma reached 30 minutes after administration.  At the same time the quality characteristics of pharmacokinetic curves go to sleep each injection were identical: a rapid rise buy proviron in drug concentration after each injection and then a slow decline to 24 hours.

Metabolism
The drug is not metabolized in the body and is excreted unchanged.

Excretion
The main elimination process takes place within 24 hours. During this period, output 80% of the administered dose: 34.8% is excreted in the time interval from 0 to 5 hours and 45.2% in the time interval from 5 to 24 chaso. Of which 77% is excreted through the intestines and 23% – in the kidney.

Indications
Treatment of influenza. If necessary, combine with the reception of symptomatic drugs

Contraindications:
Hypersensitivity of the components of the preparation. Pregnancy. Children under 18 years old.

Pregnancy and lactation
Use of the drug during pregnancy has not been studied. Use of the drug during lactation has not been studied, therefore buy proviron breast-feeding should be discontinued, if necessary, use during lactation.

Dosing and Administration
Inside, regardless of meals.
At 90 mg 1 time per day, 5 days.
The drug starts with the appearance of the first symptoms of the disease, not later than 36 hours from the onset of the disease.

Side effects:
Allergic reactions (rare).

Overdose
Cases of overdose have not been described.

Interaction with other drugs.
Cases Ingavirin ® interaction with other drugs have been identified.

Special instructions:
The drug does not have a sedative effect, does not affect the speed of psychomotor reactions and can be used in people of different professions, including requiring attention and coordination. Not recommended simultaneous reception of other buy proviron antiviral drugs.

Product form
capsules, 30 mg and 90 mg. On 7 capsules in blisters of PVC film and aluminum foil printed patent. On 90 capsules (for a dosage of 30 mg) or 60 capsules (for a dosage of 90 mg) in polymeric jars complete with lids (for hospitals). One contour package together with instructions for use placed in a pack. Banks are placed in a box made of cardboard with the application instructions on the application (for hospitals).

Storage conditions
In a dry place, protected from light and the reach of children at or above 25 ° C.

Shelf life
2 years. Do not use beyond the buy proviron expiration date.

Conditions of supply of pharmacies
by prescription. anabolic steroids online shop

buy anabolic steroids online

buy anabolic steroids online uk steroide in deutschland kaufen zuckerverzicht anabolika steroide kaufen

proviron cycle

08/24/2016

In clinical studies, after single and multiple oral kanagliflozina patients with type 2 diabetes mellitus, renal threshold for glucose dose-dependently decreased, increased excretion of glucose by the kidneys.The initial value of the renal threshold proviron cycle for glucose was approximately  the maximum reduction in the 24 hour mean renal glucose threshold observed when applying kanagliflozina 300 mg 1 time per day and varied from , which indicates a low risk of a hypoglycemia during treatment. In phase I trials in patients with type 2 diabetes treated kanagliflozin 100 mg or 300 mg, reduced renal threshold for glucose resulted in increased renal excretion of glucose at day; observed glucose excretion by the kidneys corresponds to a loss of day. Reduced renal threshold for glucose and increasing renal excretion of glucose was maintained throughout the 26-week treatment period in patients with type 2 diabetes. There was a moderate increase in the daily urine volume , which was reduced after a few days of preparation. There was a transient increase renal excretion of uric acid by the action kanagliflozina . This was accompanied by a persistent decrease proviron cycle in plasma uric acid concentration of about 20%.
The use kanagliflozina single dose of 300 mg before the mixed meal patients with type 2 diabetes caused a delay glucose absorption in the gut, and lowering postprandial glucose by the kidney and extrarenal mechanisms.
During clinical research 60 healthy volunteers received single oral kanagliflozin 300 mg, kanagliflozin a dose of 1200 mg (4-fold higher than the maximum recommended dose) or placebo, moxifloxacin. There were no significant changes in QTc interval kanagliflozina under application at the recommended dose of 300 mg, nor proviron cycle at kanagliflozina applying a dose of 1200 mg. Kanagliflozina When applied in a dose of  kanagliflozina after administration at a dose of 300 mg once a day.

Fasting
during the clinical trials application kanagliflozina as monotherapy or in addition to therapy with one or two oral hypoglycemic drugs has led to a change in the average fasting glucose from baseline compared to placebo from -1.2 mmol / L to 1.9 mmol / L kanagliflozina when used at a dose of 100 mg and 1.9 mmol / l to 2,4 mg / l – in applying kanagliflozina 300 mg, respectively. This effect was close to the maximum of the day after the first treatment and was maintained throughout the treatment period.

Postprandial glycemia
in clinical trials of kanagliflozina as monotherapy or adjunctive therapy to one or two oral hypoglycemic agents we measured postprandial blood glucose after a glucose tolerance test with a standardized mixed breakfast. Application kanagliflozina resulted in average reductions in postprandial blood glucose from baseline relative to placebo -1.5 mmol / L to -2.7 mmol / l – kanagliflozina when used at a dose of 100 mg and -2.1 mmol / l -3.5 mmol / l – application kanagliflozina at a dose of 300 mg, respectively, due to lower glucose concentration before meal and decrease postprandial glucose fluctuations.

Beta cell function
studies kanagliflozina use in patients with type 2 diabetes indicate improved beta-cell function, according to the homeostasis assessment model for beta-cell function (homeostatic model-2 assessment index% B; HOMA2-% B ), and speed improvements in insulin secretion during OGTT mixed breakfast.

Pharmacokinetic properties
Pharmacokinetics kanagliflozina in healthy subjects similar to the pharmacokinetics kanagliflozina in patients with type 2 diabetes. After a single oral kanagliflozina in doses of 100 mg and 300 mg in healthy volunteers kanagliflozin rapidly absorbed, the maximum plasma concentration (average value of the T max is reached after 1-2 hours). Plasma C max and AUC increased kanagliflozina dozoproportsionalno when used in doses from 50 mg to 300 mg. The apparent terminal half-life (t1 / 2) was 10.6 hours and 13.1 hours kanagliflozina when applied at doses of 100 mg and 300 mg, respectively. An equilibrium state was reached within 4-5 days after initiation of therapy kanagliflozinom 100 mg or 300 mg once a day.
Pharmacokinetics kanagliflozina not time dependent accumulation of drug in plasma of up to 36% after multiple dose.

Absorption
Mean absolute bioavailability kanagliflozina is approximately 65%. Eating foods high in fat did not affect the pharmacokinetics of kanagliflozina; kanagliflozin therefore can be taken with food or without it.However, given the increase in capacity kanagliflozina reduce postprandial blood glucose due to slow absorption of glucose in the intestines, it is recommended to take kanagliflozin before the first use of food.

Distribution
The mean volume of distribution at steady state kanagliflozina after a single intravenous infusion in healthy subjects was 83.5 liters, which indicates extensive tissue distribution. Kanagliflozin largely bound to plasma proteins (99%), mostly to albumin. Communication with proteins kanagliflozina independent of the plasma concentration. Communication to plasma proteins was not significantly altered in patients with renal or hepatic insufficiency.

Metabolism
O-glucuronidation is a major route of metabolism kanagliflozina. Glucuronidation occurs primarily involving UGT1A9 and UGT2B4 inactive to two O-glucuronide metabolites. Increased AUC kanagliflozina (26% and 18%) was observed in patients carriers of alleles UGT1A9 * UGT2B4 * 3 and 2, respectively. It is not expected that this effect will have clinical relevance. CYP3A4-mediated (oxidative) kanagliflozina metabolism in humans is minimal (about 7%).

Excretion
After a single dose of 14C-kanagliflozina orally to healthy volunteers 41.5%, 7.0% and 3.2% of the administered radioactive dose was detected in the feces in the form kanagliflozina, hydroxylated metabolite, and O-glucuronide metabolite, respectively. Enterohepatic circulation kanagliflozina was negligible.
Approximately 33% of the administered dose of radioactivity was detected in the urine, mainly as metabolites of O-glucuronide (30.5%). Less than 1% of the dose is excreted as unchanged kanagliflozina kidneys. Renal clearance kanagliflozina when used in doses 100 mg and 300 mg ranged from 1.30 to 1.55 ml / min.
Kanagliflozin relates to preparations with low clearance, mean systemic clearance is approximately 192 mL / min in healthy volunteers after intravenous administration.

Special patient groups Patients with impaired renal function, the C max kanagliflozina increased moderately by 13%, 29% and 29% in patients with impaired renal function mild, moderate and severe, respectively, but not in patients on hemodialysis. Compared to healthy volunteers, the serum component AUC kanagliflozina increased by approximately 17%, 63% and 50% in patients with mild, moderate and severe renal impairment, respectively, but was similar in healthy volunteers and patients with terminal chronic renal failure (CRF ). Removing kanagliflozina by dialysis was minimal.

 

Patients with impaired liver function
After applying kanagliflozina at a dose of 300 mg once daily compared to patients with normal liver function in patients with impaired hepatic function of class A on a scale Child-Pugh (dysfunction of the liver mild) indicators C max and AUC ∞ were raised on 7% and 10%, respectively, and decreased by 4% and rose by 11%, respectively, in patients with impaired liver function in class for Child-Pugh (impaired liver function moderate). These differences are not considered clinically significant. Dose adjustment in patients with hepatic impairment or mild to moderate severity is not required. Clinical experience with the drug in patients with severe hepatic impairment (class C Child-Pugh) is absent, so the use of kanagliflozina contraindicated in these patients.

Elderly patients (≥65 years)
According to the results of a population pharmacokinetic analysis, age had no clinically meaningful effect on the pharmacokinetics of kanagliflozina.

Children (<18 years)
Pharmacokinetic studies have not been conducted kanagliflozina children.

Other groups of patients
No dose adjustment based on gender, race / ethnicity, or body mass index is not required. These characteristics do not have a clinically meaningful effect on the pharmacokinetics of kanagliflozina, according to the results of a pharmacokinetic population analysis.

testimony

Type 2 diabetes in adults in combination with diet and exercise to improve glycemic control as:

  • monotherapy;
  • in a combination therapy with other hypoglycemic drugs, including insulin.

Contraindications

  • Hypersensitivity to kanagliflozinu or any excipient of the drug;
  • type 1 diabetes;
  • diabetic ketoacidosis;
  • renal insufficiency with a glomerular filtration rate (GFR) <45 ml / min / 1.73 m 2 ;
  • severe hepatic impairment;
  • lactose intolerance, lactase deficiency, glucose-galactose malabsorption;
  • chronic heart failure III – IV functional class (classification NYHA);
  • Pregnancy and breast-feeding; Children up to age 18 years.

The caution
in diabetic ketoacidosis history

Application of pregnancy and during breastfeeding

Pregnancy
kanagliflozina application studies in pregnant women have been conducted. Animal studies indicate no direct or indirect adverse toxic effects in the reproductive system. Application kanagliflozina contraindicated during pregnancy.

Breast-feeding period
is contraindicated use of kanagliflozina women during breastfeeding. According to available pharmacodynamic / toxicological data obtained in animal studies, kanagliflozin passes into breast milk. It is unknown whether kanagliflozin penetrates human milk.

Dosing and Administration

Kanagliflozin recommended ingested once daily at a dose of 100 mg or 300 mg, preferably before breakfast. The tablets should be swallowed whole.
In applying kanagliflozina as an adjunct to insulin therapy or a means of augmenting the secretion (eg sulfonylureas), to reduce the risk of hypoglycemia may be considered the use of lower doses of the above drugs.
Kanagliflozin diuretic. In patients treated with diuretics, patients with impaired moderate renal function [GFR from 45 to 60 ml / min / 1.73 m 2 ] or patients aged > 75 years have seen more frequent development of unwanted reactions associated with a decrease in intravascular volume (eg, postural dizziness, orthostatic hypotension, or hypotension). Thus, in these patients it is recommended to use kanagliflozina at an initial dose of 100 mg once a day. Patients with signs of reduced intravascular volume adjustment is recommended this condition prior to initiating treatment kanagliflozinom. Patients receiving kanagliflozin 100 mg with good tolerability and need for additional glycemic control, it is appropriate to increase the dose up to 300 mg.

Skipping doses
If you skip the dose should be taken as soon as possible; but it should not take a double dose in one day.

Special patient population Children under 18 years of age The safety and efficacy of kanagliflozina in children have not been studied.

Elderly patients
Patients aged > 75 years as an initial dose of 100 mg should be administered once a day. It is necessary to take into account the function of the kidneys and the risk of hypovolemia.

Impaired Renal Function
In patients with impaired renal function mild (the calculated glomerular filtration rate (GFR) of 60 to 90 mL / min / 1.73 m 2 ) dose adjustment is not required.
In patients with renal impairment with a glomerular filtration rate of 45 to 60 ml / min / 1.73 m 2 is recommended to use the drug at a dose of 100 mg once a day.
Kanagliflozin not recommended for use in patients with impaired renal function with a GFR <45 mL / min / 1.73 m 2 , end-stage chronic renal failure (CRF), or in patients undergoing dialysis, as expected, it would be ineffective in these patient populations kanagliflozin.

Side effect

Data on adverse drug reactions observed during clinical studies (including monotherapy and addition to metformin, metformin and a sulfonylurea, and metformin and pioglitazone) kanagliflozina with a frequency of > 2%, systematized with respect to each of the organ systems, depending on the frequency of occurrence using the following classification: very common ( > 1/10), frequent ( > 1/100, <1/10), infrequent ( > 1/1000, <1/100), rare ( > 1/10000, <1/1000) . Violations of the gastrointestinal tract: Common: constipation, nausea, thirst 1 . Uncommon: dry mouth. Violations of the kidney and urinary tract infections: Frequent: polyuria and pollakiuria 2 , urinary tract infection 3 . Infrequent: urgency to urinate ., urosepsis Violations of the genital organs and the breast: Very frequent: vulvovaginal candidiasis 4 .frequent: balanitis and balanoposthitis 5 . Infrequent:. vaginal infections 1. Category “thirst” includes the term “thirst” and “polydipsia.” 2 . “polyuria or pollakiuria” category includes the terms “polyuria”, “increase in urine volume” and “nocturia”. 3. Category “urinary tract infection” includes the term “urinary tract infection,” “cystitis” and “infection kidney “. 4. The category” vulvovaginal candidiasis “includes the terms” vulvovaginal candidiasis “,” vulvovaginal fungal infection, “” vulvovaginitis “” vulvitis “and” genital fungal infections. ” 5. Category” balanitis and balanoposthitis “includes The terms “balanitis”, “balanoposthitis ‘,’ candida balanitis” and “genital fungal infections.” in other adverse reactions that have been developed in the placebo-controlled studies kanagliflozina with a frequency of <2%, were the adverse reactions associated with a decrease in intravascular volume (postural dizziness , orthostatic hypotension, hypotension, dehydration, and syncope), skin rash, and urticaria. therapy for low testosterone hcg phase 2 food list treatment for male hypogonadism

proviron bayer

08/24/2016

Drug has immunoregulatory, detoxification, hepatoprotective effect and causes inactivation of free radical and peroxide compounds. Mode of action is based on three main effects: correction of the immune system, restoring the balance of oxidation-antioxidant response of the organism and inhibition of multidrug resistance mediated transmembrane transport proteins cell pump.The drug begins proviron bayer to develop for is manifested primarily detoxifying effect – enhanced antioxidant protection of the body by stimulating the production of ceruloplasmin, lactoferrin, catalase activity; preparation normalizes lipid peroxidation inhibits disintegration of the cell membrane phospholipids and the synthesis of arachidonic acid with subsequent reduction of blood cholesterol and the production of inflammation mediators. When toxic and infectious liver disease drug prevents cytolysis, reduces the activity of transaminases and bilirubin levels in blood serum.During the middle phase ( is amplified reactions phagocytosis and intracellular destruction of bacteria and viruses. During this period, there is normalization of immuno-regulatory code, there is an increase of production of specific antibodies. Imunofan Effect on the production of specific antiviral and antibacterial antibodies equivalent to the action of some therapeutic vaccines. Unlike the latter drug has no significant effect on the production of IgE antibodies reaginic class and does not increase the reaction of immediate type hypersensitivity;Imunofan stimulates the production of IgA in its congenital deficiency.

Imunofan effectively inhibits multidrug resistance of tumor cells and increases their sensitivity to cytostatic drugs.

Indications for use Applied in adults and children over 2 years of age for the prevention and treatment of immune deficiency and toxic conditions of acute and chronic infectious and inflammatory diseases.

Contraindications. Hypersensitivity, children up to 2 years.

Method of application and recommended dosage. Intranasal. When using the bottle should be kept upright, spray upward. Remove the protective cap from the spray. Before first use, fill the dosing pump by pressing the wide rim of the sprayer 3-4 times.Insert sprayer nostril with the head upright. Momentary push wide rim sprayer until it stops. One dose of the preparation contains 50 micrograms imunofana. The daily dose should not exceed 200 mg.

In the treatment of acute and chronic infectious and inflammatory diseases associated with symptoms of proviron bayer intoxication and immunodeficiency, imunofan appoint 1 dose (50 mcg) in each nostril 2 times a day, every day for 10 – 15 days. When opportunistic infections (cytomegalovirus, and herpes infection, toxoplasmosis, chlamydia, pneumocystis, cryptosporidiosis):

  • 1 dose (50 mg) in each nostril two times a day, daily treatment 10 – 15 days. If necessary, you can repeat the course in 2-4 weeks.

In chronic viral hepatitis and chronic brucellosis:

  • 1 dose (50 mcg) in each nostril 1 times a day, every day, a course of treatment 10 – 15 days to prevent recurrence should be repeated courses within 4 – 6 months.

In the scheme of treatment of patients with HIV infection:

  • 1 dose (50 mg) in each nostril once a day 1, daily for 10-15 days. If necessary, you can repeat the course in 2-4 weeks.

In the treatment of cancer patients in the scheme of radical combined treatment (chemotherapy, radiotherapy and surgery):

  • 1 dose (50 mg) in each nostril once a day 1, daily for 8-10 days prior to chemo-radiation therapy and surgery, followed by continuation of the course for the entire treatment period.

In patients with advanced neoplastic process (III – IV stage) of different localization in terms of the complex or symptomatic therapy:

  • 1 dose (50 mg) in each nostril once a day 1, daily for 8-10 days.

If necessary, and there are significant phenomena of toxicity it is recommended repeat the course.

Side effects. The individual intolerance.

Caution. As a result, activation of phagocytosis proviron bayer possible short-term aggravation of foci of chronic inflammation, supported by persistent viral or bacterial antigens.

. Interaction with other drugs increases the effectiveness of other types of drug therapy: the use of imunofana helps to overcome resistance to glucocorticosteroid therapy. Purpose imunofana optionally in combination with steroidal and nonsteroidal antiinflammatory drugs.

Special instructions. Due to lack of knowledge should be used with caution during pregnancy and lactation.

Product form. Imunofan®, metered nasal spray 50 mcg / dose. 40 doses in plastic bottles with a capacity of 10 ml. The vials were sealed lid fitted with a metering pump with plastic housing, nozzle and protective cap or similar dispensing device. One vial together with instructions for use placed in a pile of cardboard.

Shelf life. 2 years. Do not use the drug after the expiry date stated on the package.

Storage conditions. In the dark place at a temperature of 2 ° C to 10 ° C, out of reach of children.

Conditions of supply of pharmacies. By prescription. Steroids uk online, steroids online uk steroids online!

proviron for women

08/24/2016

Opioid receptors in the intestinal wall, resulting in inhibition of propulsive motility, increase intestinal transit time and increased resorption of water and electrolytes. Loperamide does not change the physiological intestinal microflora and increases the tone of the anal sphincter. Imodium Plus does not have a central action. Simethicone is not absorbed in the intestine, and proviron for women loperamide soaked, subjected to intensive metabolism in the liver after the first pass. As a result, the systemic circulation gets very little loperamide.
Simethicone is an inert surface-active compound having defoaming properties, and therefore alleviates the symptoms associated with diarrhea, particularly flatulence, abdominal discomfort and cramping. In humans, the half-life averages loperamide 10.8 h, ranging from 9 to 14 hours. Loperamide is well absorbed from the intestine, but almost completely metabolized in the liver and then excreted with the bile in the form of conjugated metabolites. Due to the intensive first-pass metabolism in the plasma contains very low concentrations of the unchanged loperamide. The metabolites are excreted mainly with loperamide feces. Simethicone is generally not absorbed from the gastrointestinal tract.

 

Indications for use:

Imodium Plus is indicated for diarrhea of any etiology and its attendant symptoms. Recent often caused proviron for women by intestinal gas and neothozhdeniem include abdominal discomfort, cramping and flatulence.

 

Dosage and administration:

Adults and children over 12 years of age:
Initially, 2 tablets, then 1 tablet after each loose stool. At night you can not use more than 4 tablets, the length of taking the pills should not exceed 2 days. Use in Pediatrics: Imodium Plus is not recommended for children under 12 years of age. Use in elderly patients in the treatment of elderly patients dose adjustment is necessary. Use in patients with impaired function liver and kidneys: In patients with impaired renal function there is no need to reduce the dose of Imodium Plus. Imodium Plus should be used with caution in patients with severely impaired hepatic function, as they have slowed down the metabolism of the first pass.

 

Side effect:

Loperamide has long been widely used in clinical practice and does not cause serious side effects even with proviron for women prolonged use. In rare cases it reported hypersensitivity reactions (skin rash, and urticaria), and in extremely rare cases, anaphylactic shock and bullous rash, including toxic epidermal necrolysis. In most cases these patients received concomitant medications that may also cause or contribute to the development of allergic reactions. Also reported the occurrence of constipation and / or bloating. loperamide treatment is very rarely accompanied by the occurrence of paralytic ileus, and the side effect was observed mainly in patients who do not comply with the order prescribed by a doctor taking the drug, containing loperamide. It should be emphasized that symptoms such as abdominal pain / abdominal discomfort, nausea, vomiting, fatigue, drowsiness, dizziness, dry mouth, rarely occur while taking loperamide, typical of acute diarrheal syndrome. Therefore, usually quite difficult to establish a causal relationship between taking loperamide and the emergence of these symptoms.

 

Contraindications:

Imodium Plus should not be administered to children under 12 years of age and in patients with hypersensitivity (allergy) to any ingredient of the drug.
Imodium Plus should not be used as monotherapy in acute dysentery, which is characterized by bloody diarrhea, or fever.
Imodium Plus should not be administered to patients with acute ulcerative colitis or pseudomembranous colitis associated with the treatment of broad-spectrum antibiotics.

Warnings and Precautions:
Since treatment of diarrhea with loperamide and simethicone is symptomatic, it is also necessary to carry out, whenever possible, therapy aimed at eliminating the causes of diarrhea. In patients with severe diarrhea may occur loss of fluid and electrolytes. In such cases it is necessary to carry out the appropriate replacement therapy (receiving fluids and electrolytes).
If there is no clinical improvement within 48 hours taking the pill Imodium Plus must be discontinued. Patients should be informed that in such a situation, they should consult a doctor.
Patients with severe hepatic impairment proviron for women should take Imodium Plus under the supervision of a physician.
In general, Imodium Plus should not be used in those cases when it is necessary to avoid the oppression of peristalsis; in case of constipation and / or bloating in the treatment Imodium Plus acceptance of this drug should be immediately discontinued.

Interaction with other drugs and other forms of interaction
Except drugs having similar pharmacological activity, interactions with other drugs is not detected.

Pregnancy and lactation Use during pregnancy by Currently there is no evidence that loperamide or simethicone have teratogenic or embryotoxic effect. Imodium Plus, as well as other drugs that can be taken during pregnancy, especially during the first trimester only if there is a compelling clinical indications. Use during lactation Small amounts of loperamide may enter the breast milk of women, and therefore Imodium Plus is not recommended during breast feeding.

Effect on driving and work with potentially dangerous machinery
Imodium Plus does not affect the speed of mental and physical reactions, and therefore unlikely to have a negative effect on driving a car or operating potentially dangerous machinery. However, patients who experience tiredness, dizziness or drowsiness should refrain from driving and working with potentially dangerous machinery.

Overdose Symptoms In case of overdose (including relative overdose due to hepatic dysfunction) may occur central nervous system depression (stupor, coordination disturbances, drowsiness, cramps, increased muscle tone, respiratory depression) and paralytic ileus. Children CNS depression may occur more frequently than in adults. Treatment If you have symptoms of an overdose the patient proviron for women should be entered as an antidote naloxone. Since loperamide lasts longer than naloxone (1 to 3 hours) may require repeated administration of naloxone. To detect possible CNS depression of the patient should be closely monitored for at least 48 hours.

 

Product form:

Packages containing 6 or 12 tablets

 

Storage conditions:

At a temperature of 15 to 30 ° C out of reach of children.

 

Shelf life:

2 years.
Do not use after the expiration date.

 

Conditions of supply of pharmacies:

Without a doctor’s prescription.

Buy steroids in our shop